Résumé
No active ingredient, no drug, no health product is free of side or undesirable effects. This is anticipated by the pharmaceutical companies, which research the potential risks of their product before it is marketed. Nevertheless, undesirable effects that did not appear or that were underestimated during the experimental phases may appear after marketing. When a drug is subject to a benefit/risk reassessment, especially in the context of Article 20, it is essential to know how to manage communication and how to anticipate the cessation of promotion of this drug and the management of the teams involved in its marketing... until the final decision of the health authorities on the new conditions for prescribing this drug. The search for new indications and the targeting of at-risk populations are ways that will enable the teams to remain involved in the study and presentation of this drug to the healthcare professionals and patients concerned. The discontinuation of advertising should not affect ongoing studies on new indications. This thesis presents the framework put in place by AbbVie to manage the discontinuation of the promotion of Rinvoq® (upadacitinib) in its indications and its benefit/risk reassessment by the health authorities, and the targeting of patients taking into account the probable restrictions of use.